Keppra XR® offers proven tolerability to help patients stay on therapy.1

  • Adverse events reported with Keppra XR® were generally mild to moderate
  • There were no discontinuations or dose reductions due to somnolence or irritability
Incidence Chart
*Occurring in ≥5% of patients taking Keppra XR® and at least 5% more frequently than with placebo.

Keppra XR® causes somnolence, dizziness, and behavioral abnormalities. The most common adverse reactions observed with Keppra XR® in combination with other AEDs were somnolence and irritability.

The adverse reactions that may be seen in patients receiving Keppra XR® are expected to be similar to those seen in patients receiving immediate-release Keppra® (levetiracetam) tablets.

Keppra® immediate-release tablets cause somnolence and fatigue, coordination difficulties, and behavioral abnormalities (e.g., psychotic symptoms, suicidal ideation, and other abnormalities), as well as hematological abnormalities. In adults experiencing partial-onset seizures, the most common adverse reactions observed with Keppra® in combination with other AEDs were somnolence, asthenia, infection, and dizziness.

Low discontinuation rates with Keppra XR®

  • Overall, only 5% of patients taking Keppra XR® discontinued therapy due to adverse events (vs 3% for placebo), and only 1% of patients reduced their dosage (vs 1% for placebo)
  • No discontinuations or dose reductions due to behavioral adverse events

A profile you can trust for your patients

A profile you can trust chart
†In placebo-controlled trials of Keppra® immediate-release tablets, amnesia, confusion, and abnormal thinking occurred in 1% to 1.6% of patients treated with Keppra® and in 0.3% to 1.4% of placebo-treated patients.

Favorable tolerability encourages compliance—so patients can continue to benefit from AED therapy1,4,5

  • Patients who experience fewer adverse events are more likely to comply with therapy1
  • Many neurologists believe that tolerability is an important factor in patient compliance6
IMPORTANT SAFETY INFORMATION

Keppra XR® extended-release tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.

Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Keppra XR® causes somnolence, dizziness, and behavioral abnormalities. The most common adverse reactions observed with Keppra XR® in combination with other AEDs were somnolence and irritability.

The adverse reactions that may be seen in patients receiving Keppra XR® are expected to be similar to those seen in patients receiving immediate-release Keppra® (levetiracetam) tablets.

Keppra® immediate-release tablets cause somnolence and fatigue, coordination difficulties, and behavioral abnormalities (e.g., psychotic symptoms, suicidal ideation, and other abnormalities), as well as hematological abnormalities. In adults experiencing partial onset seizures, the most common adverse reactions observed with Keppra® in combination with other AEDs were somnolence, asthenia, infection, and dizziness.

Keppra XR® should be gradually withdrawn to minimize the potential of increased seizure frequency.

Dosing must be individualized according to the patient’s renal function status. In patients with end stage renal disease on dialysis, it is recommended that immediate-release Keppra® be used instead of Keppra XR®. Please see Keppra.com for the Keppra® immediate-release tablets full prescribing information.

Please see Keppra XR® Medication Guide and Full Prescribing Information.

REFERENCES

1. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure. 1997;6:87-93.
2. Data on file. UCB, Inc.
3. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001;47:77-90.
4. Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacother. 2000;20(8 pt 2):191S-199S.
5. Steinhoff BJ, Hirsch E, Mutani R, Nakken KO. The ideal characteristics of antiepileptic therapy: an overview of old and new AEDs. Acta Neurol Scand. 2003;107:87-95.
6.  Survey data on file. UCB, Inc.

*With this coupon, your patients pay the first $25 of their Keppra XR® or Keppra® co-pay and we pay the remaining out-of-pocket expense up to a maximum of $30. This coupon may not be repsiption. No cash value. Not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. Offer expires 12/31/2012. UCB may cancel or alter this program at any time without notice.